Core Viewpoint - The launch of the innovative insomnia drug, Lemborexant (brand name: Davaiq), on Meituan marks a significant development in the treatment options available for insomnia patients in China, particularly as it is the first approved dual orexin receptor antagonist that is not classified as a controlled substance [1][2]. Group 1: Product Overview - Lemborexant is designed to treat adult patients with insomnia characterized by difficulties in falling asleep and/or maintaining sleep, and it has not been found to have addictive properties since its market introduction [1]. - The drug was approved by the National Medical Products Administration in May 2023 and is reported to shorten sleep onset time, reduce nighttime awakenings, and extend total sleep time, positively affecting sleep structure [1][2]. Group 2: Market Context - According to the "2025 China Sleep Health Survey Report," approximately 485 million people in China suffer from sleep-related issues, highlighting a significant market opportunity for insomnia treatments [1]. - Prior to Lemborexant, insomnia medications were primarily classified as controlled substances, which limited treatment options for patients [1]. Group 3: Clinical and Regulatory Insights - Clinical trials indicate that Lemborexant has minimal impact on memory and cognitive function, allowing patients to resume daily activities, including driving, without significant impairment [2]. - The drug has been included in the "Chinese Adult Insomnia Diagnosis and Treatment Guidelines (2023 Edition)" as an IA-level recommendation, further validating its clinical efficacy [2]. Group 4: Distribution and Accessibility - Meituan has facilitated the purchase of Lemborexant through its platform, allowing patients to order the medication with a prescription and receive it via home delivery within 48 hours, with compensation offered for any delays [2]. - The trend of online platforms becoming significant channels for new drug purchases is growing, with Meituan having launched seven new drugs since last year, covering various therapeutic areas including GLP-1, myopia, gout, and insomnia [2].